A study presented at this year’s meeting of the European Association for the Study of Diabetes showed that diabetic patients who use insulin therapy guided by Glytec‘s Glucommander software achieved glucose control quickly and successfully maintained A1C reductions long-term, the company reported today.
Once a patient gets their blood sugar into range, the Glucommander software remains active. The technology performs analyses to determine if insulin dose adjustments are needed, according to Glytec, and monitors patients to identify out-of-range highs or lows.
The 74-patient study presented at EASD had a median time between insulin dose adjustments of 57 days.
“This means that once Glucommander titrated these patients to goal, continued analyses of patterns in their blood glucose indicated that additional insulin dose adjustments were needed, on average, every eight weeks,” CMO Dr. Andrew Rhinehart said in prepared remarks. “This confirms that the usual and customary practice of patients waiting three to six months for a follow-up visit is not sufficient to maintain glucose control and may increase risks of hyperglycemia and hypoglycemia. The study substantiates that ongoing and more frequent insulin titration, performed in a virtual manner, enables patients to maintain A1C reductions over time.”
Severe hypoglycemia as a percent of blood glucose values was 0.05%, Glytec reported, consistent with previous studies. It also took study participants a median time of seven days to reach their prescribed glucose goal.
“We’ve been very purposeful in our design of Glucommander Outpatient to ensure maximum efficiency, scalability and ease of use for clinicians,” SVP of R&D, Robby Booth, added. “They don’t have to wade through droves of data to perform manual calculations, and they don’t have to question whether or when it’s appropriate to make dose adjustments. And because this happens remotely, an intervention takes only a couple of minutes, which translates to less time and overhead in treating patients with diabetes, better margins and greater profitability.”
See the best minds in medtech live at DeviceTalks Boston on Oct. 2.
